Thane Wettig
2021
Compensation breakdown
| Non-Equity Incentive Plan | $186,533 |
|---|---|
| Option Awards | $1,590,542 |
| Salary | $510,000 |
| Stock Awards | $874,665 |
| Other | $12,855 |
| Total | $3,174,595 |
Wettig received $1.6M in option awards, accounting for 50% of the total pay in 2021.
Wettig also received $186.5K in non-equity incentive plan, $510K in salary, $874.7K in stock awards and $12.9K in other compensation.
Rankings
In 2021, Thane Wettig's compensation ranked 4,217th out of 12,406 executives tracked by ExecPay. In other words, Wettig earned more than 66.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,217 out of 12,406 | 66th |
Division Manufacturing | 1,737 out of 5,494 | 68th |
Major group Chemicals And Allied Products | 723 out of 2,369 | 70th |
Industry group Drugs | 645 out of 2,090 | 69th |
Industry Pharmaceutical Preparations | 455 out of 1,537 | 70th |
Pay ratio
| Thane Wettig's Pay | $3,174,595 |
|---|---|
| Median Employee's Pay | $174,414 |
| Pay Ratio | 18to 1 |
In 2021, the annual total compensation of Thane Wettig was $3,174,595.
The annual total compensation of the median employee at FibroGen was $174,414.
The ratio of Thane Wettig's pay to the pay of median employee was therefore 18 to one.
Wettig's colleagues
We found six more compensation records of executives who worked with Thane Wettig at FibroGen in 2021.
2021
Enrique Conterno
FibroGen
Chief Executive Officer
2021
Christine Chung
FibroGen
Senior Vice President, China Operations
2021
Mark Eisner
FibroGen
Chief Medical Officer
2021
Pat Cotroneo
FibroGen
Chief Financial Officer
2021
Elias Kouchakji
FibroGen
Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance
2021
Juan Graham
FibroGen